Clinical trials: in New Zealand
Psoriasis
Evaluate the Safety and Pharmacokinetics/Pharmacodynamics of HS-20118
The study will be conducted in 2 parts (SAD for Part 1 and MAD for Part2). Part 1 is a single-center, randomized, double-blind, placebo-controlled, SAD study to evaluate the safety, tolerability, immunogenicity, and PK of…
- Trial name
- NCT06846710
- Testing
- HS-20118
- Where
- 9 sites in United States, New Zealand
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Hypertension (HTN), Healthy Adult Participants
Study of AB-110 in Healthy and Hypertensive Participants
This Phase 1, randomized, double-blind study is designed to evaluate safety, tolerability, PK, and PD effects of AB-110. This study will be conducted in 2 parts: a single ascending dose (SAD; Part A) in healthy participants with…
- Trial name
- NCT07916961
- Testing
- Active drug
- Where
- New Zealand
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Antlia Bioscience, Inc
Atopic Dermatitis (AD)
A Phase 1/1b Study to Evaluate Safety, Tolerability and Pharmacokinetics of ZL-1503 in Healthy Volunteers and Participants With Moderate to Severe Atopic Dermatitis
This is a phase 1/1b randomized, double blind, placebo-controlled, single dose escalation (SAD) and multiple dose escalation (MAD) study to evaluate the safety, tolerability, and pharmacokinetics (PK) of ZL-1503 in healthy…
- Trial name
- NCT07235384
- Testing
- ZL-1503
- Where
- 14 sites in Australia, China and 1 more
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Zai Lab (Shanghai) Co., Ltd.
Tinnitus
A Study of the Safety and Efficacy of TRTL-913 in Healthy Volunteers (Part A) and in Adults With Tinnitus (Part B)
This study will consist of two parts. Double blind Part A will assess the safety, tolerability, and pharmacokinetics of 7 days of dosing in healthy adults, while open label Part B will evaluate the safety, tolerability, and…
- Trial name
- NCT07777549
- Testing
- TRTL-913
- Where
- 10 sites in Australia, New Zealand
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Tortugas Neuroscience, Inc.
Moderate-to-severe Atopic Dermatitis
Phase 1a/1b Study of TRB-061 in Healthy Participants & Patients With Atopic Dermatitis
This Phase 1a/1b randomized, double-blind, placebo-controlled study evaluates the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of subcutaneously (SC) administered TRB-061 in healthy adults and patients with…
- Trial name
- NCT06934252
- Testing
- TRB-061
- Where
- 19 sites in Australia, New Zealand
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- TRex Bio, Inc.
Hyperlipidemia
A Study to Evaluate COR-1004 in Adult Volunteers.
This research study is being done to see if a new, injectable drug called COR-1004 is safe for people to take. It will also help doctors find the right dose of the drug.
- Trial name
- NCT07229118
- Testing
- COR-1004
- Where
- 2 sites in New Zealand
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Corsera Health
Healthy Volunteers
A Study to Test a Single Dose of a New Tablet Formulation of TRTL-729
This study assesses the safety, tolerability, and pharmacokinetics (PK) of the tablet formulation of TRTL-729 in healthy adults.
- Trial name
- NCT07811063
- Testing
- TRTL-729
- Where
- New Zealand
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Tortugas Neuroscience, Inc.
Healthy
A Study to Evaluate Single-dose of HB0056 in Healthy Adult Participants
The aim of this study is to investigate the safety and tolerability of HB0056 in healthy subjects following single-dose.
- Trial name
- NCT06612970
- Testing
- HB0056
- Where
- New Zealand
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd.
Healthy, Obesity, Metabolically
A First in Human (FIH) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DR10624
DR10624 is an Fc fusion protein tri-agonist with balanced glucagon-like peptide-1 receptor (GLP-1R)/glucagon receptor (GCGR)/ fibroblast growth factor 21 receptor (FGF21R) agonizing activities.
- Trial name
- NCT05378893
- Testing
- DR10624 for injection
- Where
- New Zealand
- Volunteers
- 153 people, healthy volunteers welcome
- Sponsor
- Zhejiang Doer Biologics Co., Ltd.
Healthy Volunteers
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7806881 in Healthy Participants
The main purpose of this study is to evaluate the safety and tolerability of single and multiple ascending doses of RO7806881 in healthy participants.
- Trial name
- NCT07271693
- Testing
- RO7806881
- Where
- New Zealand
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Shingles, Herpes Zoster
Safety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults 50 Years of Age and Over
This is a randomized, active-controlled, observer-blinded, dose-escalation multi-center trial of 2 doses of an investigational HZ vaccine (Z-1018) in approximately 764 healthy adults.
- Conditions
- Shingles, Herpes Zoster, Vaccine-Preventable Diseases
- Trial name
- NCT06569823
- Testing
- Z-1018, Shingrix
- Where
- 16 sites in Australia, New Zealand
- Volunteers
- 764 people, healthy volunteers welcome
- Sponsor
- Dynavax Technologies Corporation
Mild Hepatic Imparement
A Study to Assess the Safety, Tolerability and Pharmacokinetics of ABI-6250 in Participants With Mild Hepatic Impairment Compared With Participants With Normal Hepatic Function
This study is designed to assess the safety, tolerability and pharmacokinetics of ABI-6250 in participants with mild hepatic impairment compared with participants with normal hepatic function.
- Trial name
- NCT07850999
- Testing
- ABI-6250
- Where
- New Zealand
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Assembly Biosciences
Androgenetic Alopecia (AGA)
A Study to Evaluate Safety and Efficacy of OLX72021 in Healthy Males With Androgenetic Alopecia
This study is designed to evaluate the safety, efficacy, tolerability, and pharmacokinetics (PK) of OLX72021 in medically healthy men with mild to moderate androgenetic alopecia.
- Trial name
- NCT07327359
- Testing
- OLX72021
- Where
- 8 sites in Australia, New Zealand
- Volunteers
- 158 people, healthy volunteers welcome
- Sponsor
- Olix Pharmaceuticals, Inc.
Psoriasis
A Study of HCXT-2001 Tablets and HCXT-2001 Tablets(A) in Healthy Adults
The goal of this intervention study is to assess the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of HCXT-2001 Tablets and HCXT-2001 Tablets(A) in Healthy Participants.
- Trial name
- NCT07792928
- Testing
- HCXT-2001 Tablets, HCXT-2001 Tablets(A)
- Where
- 3 sites in New Zealand
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Shanghai Peptidstar Therapeutics Limited
Healthy Volunteers
ORKA-002-211 A Phase I Study to Evaluate ORKA-002 in Healthy Volunteers Following A Single Dose
This is a Phase 1, first-in-human study to evaluate the safety, tolerability, and pharmacokinetics of ORKA-002 in healthy participants.
- Trial name
- NCT06944379
- Testing
- ORKA-002
- Where
- New Zealand
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Oruka Therapeutics, Inc.
Healthy
A Study of LY4088044 in Healthy Participants
The purpose of this study is to evaluate how well LY4088044 is tolerated and what side effects may occur in healthy participants.
- Trial name
- NCT07090785
- Testing
- LY4088044
- Where
- 6 sites in United States, New Zealand and 1 more
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy Volunteers, Chronic Kidney Disease
A Study to Investigate IGT-303 in Healthy Volunteers and Participants With Chronic Kidney Disease
The goal of this clinical trial is to observe the safety of IGT-303 in healthy volunteers and participants with Chronic Kidney Disease.
- Trial name
- NCT07231679
- Testing
- IGT-303
- Where
- 13 sites in United States, Australia and 2 more
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Ingenia Therapeutics INC
Healthy Volunteers
SAD and MAD Study of AKB-9090 in Healthy Adult Participants
This is a first-in-human (FIH study designed to evaluate safety, tolerability, pharmacokinetic, and pharmacodynamic effects of AKB-9090 in healthy adult participants.
- Trial name
- NCT07429006
- Testing
- AKB-9090
- Where
- New Zealand
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Akebia Therapeutics
Otherwise Healthy Individuals With Systolic Blood Pressure (SBP) From 110 to 139 mmHg and Low-density Lipoprotein Cholesterol (LDL-C) ≥ 100 mg/dL
A Study to Evaluate COR-2003 as Monotherapy and Co-Administered With COR-1004 in Adult Volunteers
This clinical trial has two parts. In Part A, the goal is to learn about the safety and tolerability of COR-2003 when it is given alone.
- Trial name
- NCT07858019
- Testing
- COR-2003, COR-1004 + COR-2003
- Where
- 2 sites in Australia, New Zealand
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Corsera Health
Respiratory Syncytial Virus Infections
An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study
The purpose of this study is: To investigate the optimal timing for revaccination after the initial RSVPreF3 OA vaccine dose, To evaluate the long-term immune persistence and safety up to 5 consecutive RSV seasons (approximately…
- Trial name
- RSV OA=ADJ=012 (NCT06534892)
- Testing
- RSVPreF3 OA vaccine
- Where
- 251 sites in United States, Australia and 15 more
- Volunteers
- 10,212 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline